Gamma-aminobutyric acid type A receptor benzodiazepine binding site (GABA_A receptor BZD site) (GABA_A receptor BZD site)

The Gamma-aminobutyric acid type A (GABA_A) receptor benzodiazepine site is a high-affinity allosteric binding pocket located at the interface of the alpha (α1, α2, α3, or α5) and gamma (γ2) subunits of the pentameric GABA_A receptor complex (Sigel & Steinmann, 2012, PubMed). This site is distinct from the orthosteric GABA binding site and serves as the primary molecular target for benzodiazepines, such as diazepam, and non-benzodiazepine "Z-drugs" like zolpidem (StatPearls, 2023). Upon ligand binding, the site undergoes conformational changes that increase the receptor's affinity for GABA, thereby increasing the frequency of chloride channel opening and enhancing inhibitory postsynaptic currents (UniProt, 2024). This enhancement of GABAergic tone results in the characteristic pharmacological effects of these drugs, including sedation, anxiolysis, muscle relaxation, and anticonvulsant activity. Clinically, this site is targeted to treat a variety of conditions such as generalized anxiety disorder, insomnia, and acute seizures (NIH, 2023). However, the widespread distribution of these receptors in the central nervous system leads to significant side effects, including cognitive impairment, motor incoordination, and a high potential for physical dependence and withdrawal (FDA, 2020). Research into subtype-selective ligands aims to isolate specific therapeutic effects, such as targeting α2/α3-containing receptors for anxiolysis without the sedation associated with α1-containing receptors (PubMed, 2021).

Other names

Benzodiazepine receptorBZD siteGABA_A receptor alpha/gamma interfaceOmega receptorBZ receptor

Positive allosteric modulation of the GABA_A receptor, increasing the frequency of chloride channel opening in the presence of GABA (Sigel & Steinmann, 2012).